This article is more than 5 years old. Information may no longer be current.
ASH announces training program participants
Click Here to Manage Email Alerts
ASH and the European Hematology Association released the names of 20 early-career hematologists who are participating in the 2015 Translational Research Training in Hematology joint program.
The TRTH program, in its sixth year, helps junior scientists build successful careers in hematologic translational research through a rigorous year-long training and mentoring experience. Participants include medical, biomedical and pharmaceutical doctorate trainees actively employed in a hematology-related research environment who are junior faculty or program leaders and have completed their fellowship training within the past 3 years.
David A. Williams
“By honing critical skills, such as how to investigate the pathogenesis of hematologic disorders and how to design new diagnostic tests and therapies, TRTH participants are building a strong foundation for their careers in translational research,” ASH President David A. Williams, MD, of Boston Children’s Hospital, said in a press release. “As a former faculty of this program, I appreciate the dedication to translational research of the trainees and also the unique opportunity TRTH provides these trainees to learn how to take science from the bench to patients.”
The participants are Ileana Anthony Debre, PhD, of Albert Einstein College of Medicine; Pavan Bachireddy, MD, of Dana-Farber Cancer Institute; Lucile Couronne, MD, PhD, of Necker Hospital in Paris; Moniek DeWitte, MD, PhD, of Medical Center Utrecht in the Netherlands; Ammon Fager, MD, PhD, of Duke University Medical Center; Emir Hadzijusufovic, DVM, of Medical University of Vienna; Gillian Horne, MD, of University of Glasgow; Moonjung Jung, MD, of the National Heart, Lung, and Blood Institute; Jonas Samuel Jutzi, MD, of University Medical Center Freiburg in Germany; Milka Koupenova-Zamor, PhD, of University of Massachusetts Medical School; Marwan Kwok, MD, of University of Birmingham; Patricia Maiso, PhD, of Clinica Universidad de Navarra in Spain; Jean-Baptiste Micol, MD, of Memorial Sloan Kettering Cancer Center; Christopher Ott, PhD, of Dana-Farber Cancer Institute; Carsten Riether, PhD, of University of Bern/Inselpsital in Switzerland; Anindita Roy, PhD, of Imperial College London; Melody Smith, MD, of Memorial Sloan Kettering Cancer Center; Zuzana Tothova, MD, PhD, of Brigham and Women’s Hospital; Marin Wlodarski, MD, PhD, of University of Freiburg in Germany; and Yuh-Ying Yeh, PhD, of The Ohio State University.